Glycosyltransferases and Glycosidases: Functions and Mechanisms
Explore how glycosyltransferases and glycosidases build, process and degrade glycans. Learn about sugar donors, catalytic mechanisms, enzyme families, N-glycan processing and biotechnology applications.
When Glycans Change the Cellular Landscape.
Discover how cancer-associated glycosylation changes influence cell recognition, receptor signaling, adhesion, immune interactions and the search for molecular biomarkers.
Explore branched N-glycans, truncated O-glycans, sialylation, fucosylation, tumor-associated carbohydrate antigens and the analytical challenges of translating glycan signatures into clinical information.
Glycans in cancer often show altered branching, sialylation, fucosylation and O-glycosylation patterns. These changes may influence tumor-cell adhesion, receptor signaling, migration, immune recognition and interactions with the tumor microenvironment. Some carbohydrate epitopes, including sialyl-Lewis A, are used as biomarkers, while many others remain under research or clinical evaluation.
What Are Glycans in Cancer?
Cancer glycobiology studies how glycan structures, glycosylation pathways and carbohydrate-recognition systems change during tumor development, progression and interactions with surrounding tissues.
All mammalian cells display glycans on proteins and lipids. Together with other extracellular components, these molecules contribute to the glycocalyx, a carbohydrate-rich interface that affects cellular communication and recognition.
During malignant transformation, changes in gene expression, cell metabolism, enzyme localization and biosynthetic pathways may alter the glycans attached to proteins and lipids.
Why is glycosylation relevant to cancer?
Receptor Regulation
Glycan modifications can affect receptor localization, stability and molecular interactions.
Cellular Contacts
Glycan-dependent interactions may influence cell adhesion, migration and tissue organization.
Immune Recognition
Tumor-associated glycan motifs can interact with lectins on immune and stromal cells.
Are tumor-associated glycans unique to cancer?
Not always. Some glycan motifs are enriched in particular tumors but may also appear in healthy, developing or inflamed tissues. The biological interpretation depends on the exact structure, abundance, tissue localization and molecular context.
A glycan pattern can therefore be biologically informative without being sufficiently specific to diagnose cancer.
Scientific reference: Glycosylation Changes in Cancer — Essentials of Glycobiology .
Major Glycosylation Changes in Cancer
Cancer-associated glycan changes frequently involve altered N-glycan branching, terminal sialylation, fucosylation and the processing of mucin-type O-glycans.
The direction and magnitude of these alterations depend on cancer type, tumor stage, cell state and the specific glycoproteins or glycolipids studied. A pattern reported in one tumor should not be generalized to all cancers.
Common molecular alterations
| Alteration | Molecular feature | Research significance |
|---|---|---|
| Altered sialylation | Changes in terminal sialic-acid residues | Lectin recognition, immune regulation and adhesion |
| Altered fucosylation | Changes in core or terminal fucose | Receptor biology and glycoform biomarkers |
| N-glycan branching | Different antennae and branch structures | Receptor organization and signaling |
| Truncated O-glycans | Tn, STn and related short motifs | Tumor-associated antigens and molecular recognition |
| Changes in mucins | Altered glycan density and composition | Glycocalyx organization and tissue interactions |
| Glycosphingolipid changes | Altered glycolipid carbohydrate headgroups | Cellular recognition and selected therapeutic targets |
What drives these changes?
Glycosyltransferases
Changes in enzymes such as sialyltransferases, fucosyltransferases and N-glycan branching enzymes can influence glycan distributions.
Metabolic and Secretory Pathways
Nucleotide-sugar availability, Golgi organization, protein trafficking and other cellular properties affect glycan production.
Reference: Glycosylation in Cancer: From Functional Roles to Therapeutic Implications (2026) .
Truncated O-Glycans: Tn, T and Sialyl-Tn
Mucin-type O-GalNAc glycosylation is frequently remodeled in carcinomas. Altered glycan extension and terminal modification can expose short carbohydrate motifs, including Tn and STn.
The Tn antigen consists of GalNAc linked to a suitable amino acid hydroxyl group. Sialyl-Tn (STn) is a sialylated derivative of the Tn structure.
The T antigen, also called the Thomsen–Friedenreich antigen, contains a galactose residue linked to the GalNAc core. These motifs may occur on mucins and other glycoproteins.
O-glycan motif comparison
| Antigen | Simplified structure | Biological context |
|---|---|---|
| Tn | GalNAcα-O-Ser/Thr | Short O-GalNAc glycan associated with some tumors |
| Sialyl-Tn | Neu5Acα2-6GalNAcα-O-Ser/Thr | Sialylated short O-glycan |
| T / TF | Galβ1-3GalNAcα-O-Ser/Thr | Core 1 O-GalNAc glycan motif |
How do truncated O-glycans arise?
Possible mechanisms include altered glycosyltransferase expression, impaired core 1 synthesis, disrupted Golgi organization and changes in competition between glycan-extension pathways.
For example, loss of functional C1GALT1 activity, including through defects in its chaperone COSMC, can prevent normal core 1 extension and contribute to Tn antigen accumulation.
Other pathways, including activity of ST6GALNAC-family enzymes, can influence STn production. The mechanism depends on cellular context.
N-Glycan Branching and Fucosylation
N-linked glycans are attached to suitable asparagine residues on proteins. In many tumors, changes in glycan processing can alter branch organization, terminal residues and interactions with glycan-binding proteins.
Branching and receptor behavior
MGAT-family glycosyltransferases participate in construction of complex N-glycan branches. Depending on the cellular system, changes in branching may influence glycoprotein organization, receptor interactions and signaling behavior.
For example, increased MGAT5-dependent branching can promote selected galectin-associated receptor interactions in experimental cancer models. These mechanisms cannot be assumed to apply equally to every tumor.
Core versus terminal fucosylation
FUT8-Dependent Modification
FUT8 adds α1,6-linked fucose to the innermost GlcNAc of suitable N-glycan acceptors. This modification can influence specific glycoprotein properties.
Lewis Antigen Formation
Other fucosyltransferases participate in formation of selected terminal glycan epitopes, including Lewis-related structures.
| Molecular feature | Relevant enzymes | Research question |
|---|---|---|
| N-glycan branching | MGAT family | How does branch topology affect protein interactions? |
| Core fucosylation | FUT8 | Which glycoproteins carry altered core fucose? |
| Terminal fucosylation | Selected FUT enzymes | Which Lewis-type epitopes are formed? |
| Terminal sialylation | Selected sialyltransferases | How are recognition motifs altered? |
Why study the glycosylation site?
A single protein may have multiple glycosylation sites. The glycan distribution can differ between sites and between tumor and non-tumor samples.
Site-specific glycoproteomics can therefore offer more molecular context than measurement of a single released-glycan composition.
Reference: Prutisto-Chang et al. (2026), Glycosylation in Cancer .
Sialylation, Siglecs and Immune Evasion
Sialic acids are frequently found at the termini of glycans. In some cancers, altered sialylation can modify interactions with Siglec receptors expressed by immune cells.
Siglecs are sialic-acid-binding immunoglobulin-like lectins. Several Siglec receptors can transmit inhibitory signals, although their functions and cell-type distributions vary.
The sialic acid–Siglec axis
Selected sialylated glycans on tumor cells can engage specific immune-cell Siglecs. Under suitable conditions, these interactions may contribute to an immunoregulatory environment.
Other glycan-binding proteins
Sialic Acid Recognition
Selected Siglecs recognize specific sialylated motifs and influence immune-cell signaling in context-dependent ways.
Beta-Galactoside Recognition
Galectins bind appropriate glycan motifs and can influence receptor organization, immune regulation and adhesion.
Cellular Adhesion
Selectin interactions with selected glycans participate in leukocyte trafficking and may influence tumor-associated adhesion processes.
Is the Siglec pathway a cancer therapy?
The sialic acid–Siglec axis is an active area of immunotherapy research. Strategies under investigation include glycan-targeted approaches and interference with selected inhibitory receptor interactions.
The effectiveness and safety of individual strategies must be established in appropriate preclinical and clinical studies.
Glycans in Cell Adhesion, Migration and Metastasis
Cancer progression involves multiple biological processes, including changes in cellular adhesion, extracellular-matrix interactions, migration and tissue invasion. Glycans can modulate selected molecular pathways involved in these processes.
Cell–cell adhesion
Glycosylation changes on cell-adhesion proteins, including cadherins in some experimental systems, can alter their molecular properties and interactions.
However, altered glycans should not be treated as a universal cause of tumor dissociation. Cell signaling, transcriptional programs and other molecular processes also contribute.
Cell–matrix interactions
Integrins and other cell-surface glycoproteins can be modified by diverse glycan structures. These changes may influence their interaction networks and cellular behavior.
Metastasis-associated glycans
| Glycan feature | Potential molecular interaction | Research context |
|---|---|---|
| Sialyl-Lewis motifs | Selected selectin interactions | Adhesion and vascular interaction models |
| Branched N-glycans | Receptor and galectin interactions | Migration and signaling studies |
| Core fucosylation | Context-specific glycoprotein changes | Selected invasion and metastasis models |
| Truncated O-glycans | Mucin and lectin-associated interactions | Cell-surface remodeling |
This sequence represents a testable research model, not a mandatory progression followed by every cancer.
Separating association from mechanism
A correlation between a glycan epitope and tumor progression does not establish causality. Strong mechanistic evidence may require targeted perturbation of biosynthetic enzymes, rescue experiments, direct structural analysis and appropriate biological models.
Reference: Munkley (2016), Hallmarks of glycosylation in cancer .
Cancer Glycan Biomarkers: CA19-9, STn and Beyond
Some cancer-associated glycan epitopes are used in clinical laboratory testing, while many others remain experimental. Their intended use, specificity and clinical interpretation vary substantially.
CA19-9 and sialyl-Lewis A
CA19-9 is associated with the carbohydrate antigen sialyl-Lewis A. It is commonly measured in the clinical management of pancreatic and certain other cancers.
However, CA19-9 levels can be elevated in nonmalignant conditions. Some individuals also produce little or no CA19-9 due to their glycosylation phenotype.
Consequently, CA19-9 should not be used alone to screen for or diagnose pancreatic cancer. Its interpretation requires clinical context and other appropriate investigations.
Representative biomarker candidates
| Marker or feature | Molecular basis | Evidence context |
|---|---|---|
| CA19-9 | Sialyl-Lewis A carbohydrate antigen | Established clinical-use marker with important limitations |
| CA125 | Marker associated with the heavily glycosylated protein MUC16 | Clinical-use marker; not itself a single defined glycan structure |
| Tn antigen | Truncated O-GalNAc structure | Investigational tumor-associated carbohydrate antigen |
| Sialyl-Tn | Sialylated Tn antigen | Investigational glycan biomarker and therapeutic target |
| Sialyl-Lewis X | Sialylated and fucosylated Lewis motif | Research marker in selected tumor contexts |
| Selected fucosylated glycoforms | Protein- and site-associated fucosylation | Research applications and context-specific clinical use |
Why glycoform context matters
The same glycan motif may appear on different glycoproteins and glycolipids. Combining glycan structure with the identity of the carrier molecule can provide additional biological information.
Site-specific glycoproteomics allows researchers to investigate whether particular protein glycosylation sites carry disease-associated glycoform distributions.
Research example: Glycans related to the CA19-9 antigen in pancreatic cancer .
How Researchers Analyze Cancer-Associated Glycans
Cancer glycan characterization often requires complementary methods because individual techniques measure different aspects of a glycan population.
Mass spectrometry can reveal glycan composition and fragmentation information. Glycoproteomics can connect modifications to specific proteins and sites. Lectin assays, imaging and histological approaches provide other molecular or spatial information.
Comparison of analytical methods
| Method | Primary information | Major limitation |
|---|---|---|
| Released glycan LC-MS | Glycan composition and relative profiles | Original protein-site context may be lost |
| Glycopeptide LC-MS/MS | Protein-linked glycosylation sites and glycoforms | Site localization and glycan isomers can remain ambiguous |
| Lectin arrays | Selected glycan-binding patterns | Overlapping lectin specificity |
| Glycan-directed antibodies | Selected carbohydrate-associated epitopes | Binding may depend on carrier and presentation |
| Immunohistochemistry | Spatial distribution of selected markers | Probe validation and tissue specificity |
| NMR spectroscopy | Detailed molecular connectivity for suitable samples | Purity and sample-quantity requirements |
Cancer glycan biomarker discovery pipeline
Why independent validation matters
Candidate biomarkers can be affected by age, inflammation, sample handling, batch effects, tumor heterogeneity and other confounding factors.
Independent validation should assess whether the marker performs consistently across clinically relevant populations and whether it provides information beyond existing tests.
Glycan-Targeted Therapies and Frequently Asked Questions
Cancer-associated glycans are being investigated as therapeutic targets and potential determinants of treatment response. Different approaches aim to recognize carbohydrate epitopes, modify glycosylation or affect glycan-binding receptor pathways.
Therapeutic research directions
Glycan-Directed Antibodies
Antibodies may recognize selected carbohydrate epitopes or specific glycopeptide combinations.
Siglec-Related Strategies
Selected approaches attempt to modify immunoregulatory sialic-acid interactions.
Glycosylation Modulation
Research investigates enzymes and pathways involved in creating tumor-associated glycans.
These approaches have different levels of experimental and clinical evidence. They should not be treated as equivalent to established cancer therapies.
Frequently asked questions
What are glycans in cancer?
They are carbohydrate structures on proteins, lipids and other molecules whose composition, abundance or organization may change in cancer cells and their microenvironment.
How does glycosylation change in cancer?
Some tumors show changes in sialylation, fucosylation, N-glycan branching and mucin-type O-glycan processing. The pattern depends on the cancer and molecular context.
Are all cancer-associated glycans unique to tumors?
No. Many glycan epitopes are also found in nonmalignant tissues. Their abundance, localization or molecular presentation may differ in tumors.
What are Tn and sialyl-Tn antigens?
Tn is a short O-GalNAc carbohydrate structure. Sialyl-Tn is its sialylated derivative. Both are under investigation as tumor-associated carbohydrate antigens.
What is CA19-9?
CA19-9 is a blood-test marker associated with sialyl-Lewis A. It is used in selected clinical contexts, particularly pancreatic cancer management, but is not sufficiently specific or sensitive as a stand-alone screening or diagnostic test.
Can glycosylation influence cancer immunity?
Yes. Selected glycans can interact with Siglecs, galectins and other glycan-binding proteins, which can modify immune responses in specific contexts.
Does increased sialylation always cause immune evasion?
No. The effects depend on the precise sialylated structure, binding receptor, cell type and tumor microenvironment.
Can mass spectrometry detect cancer-associated glycans?
Yes. Glycomics and glycoproteomics workflows can analyze glycan populations and selected protein-associated glycoforms. Structural ambiguity may require complementary methods.
Can glycans predict cancer prognosis?
Some glycan patterns are associated with clinical outcomes in specific studies. Clinical prognostic use requires appropriate independent validation.
Are glycan-targeted cancer therapies available?
Some approved cancer treatments target glycan-associated antigens, while numerous other glycan-directed strategies are investigational. Availability and evidence depend on the exact therapy and cancer indication.
Research challenges
Cancer glycan biology is complicated by tumor heterogeneity, multiple glycan isomers, enzyme redundancy, variable expression and differences between experimental models and human tumors.
Progress requires mechanistic studies, validated analytical methods, clinically representative cohorts and careful assessment of potential off-tumor effects.
Conclusion and Scientific References
Glycans represent an important molecular layer of cancer biology. Changes in glycan branching, terminal modifications and biosynthetic processing can affect glycoprotein behavior, cellular recognition, adhesion and interactions with the tumor microenvironment.
Truncated O-glycans, altered sialylation and fucosylation, and changes in N-glycan architecture are widely studied, but their biological effects are context-dependent.
Glycan analysis also creates opportunities for biomarker research and therapeutic development. However, translating molecular patterns into clinical applications requires substantial analytical and clinical validation.
Structure changes recognition. Recognition may influence disease.
Understanding tumor-associated glycans requires connecting molecular composition, biosynthetic pathways, glycoprotein context, immune interactions and experimental evidence.
Verified peer-reviewed scientific references
- Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nature Reviews Cancer. 2015;15:540–555. DOI: 10.1038/nrc3982 .
- Prutisto-Chang K, Batu T, Jame-Chenarboo F, Hernando E, Mahal LK. Glycosylation in Cancer: From Functional Roles to Therapeutic Implications. Annual Review of Cancer Biology. 2026;10:113–134. Read review .
- Glycosylation Changes in Cancer. In: Essentials of Glycobiology. 4th edition. Cold Spring Harbor Laboratory Press; 2022. Read scientific textbook chapter .
- Munkley J. Hallmarks of glycosylation in cancer. Oncotarget. 2016;7(23):35478–35489. DOI: 10.18632/oncotarget.8155 .
- van Vliet SJ, van Kooyk Y. Sialic acids in cancer biology and immunity—recent advancements. Journal of Biological Chemistry. 2025;301(10):110641. Read research review .
- Tumor Glycosylation: A Main Player in the Modulation of Immune Responses. European Journal of Immunology. 2025;55(3):e202451318. Journal reference .
- Cancer-associated alterations in O-GalNAc glycosylation. Glycobiology. 2026;36(9):cwag049. Read 2026 review .
- Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers. Proteomics Clinical Applications. 2013. Read research review .
- Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9. Peer-reviewed biomarker study. PubMed record .
Explore the Unique Carbio Knowledge Base
Cancer glycobiology connects fundamental glycan structures with glycosylation pathways, analytical technologies, molecular recognition and biomedical research.
Scientific educational content only. Disease associations, proposed biomarkers and investigational therapies must be interpreted according to their specific level of experimental and clinical evidence.